Canton Strategic Holdings (CNTN) Cash & Equivalents (2020 - 2026)
Canton Strategic Holdings (CNTN) posted Cash & Equivalents of $41.5 million for Q1 2026, up 143.84% on a QoQ basis from $17.0 million in Q4 2025, and up 3760.12% year-over-year from $1.1 million in Q1 2025.
Canton Strategic Holdings (CNTN) Cash & Equivalents (2020 - 2026) Analysis & Trends
Canton Strategic Holdings' Cash & Equivalents history runs 7 years deep, the most recent figure standing at $41.5 million for Q1 2026.
- Quarterly Cash & Equivalents rose 3760.12% year-over-year to $41.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $41.5 million (up 3760.12% YoY) and the FY2025 annual result came in at $17.0 million, up 378.53% from the prior year.
- Cash & Equivalents was $41.5 million for Q1 2026 at Canton Strategic Holdings, up from $17.0 million in the prior quarter.
- Across five years, Cash & Equivalents topped out at $41.5 million in Q1 2026 and bottomed at $1.1 million in Q1 2025.
- A 5-year average of $8.8 million and a median of $7.6 million in 2022 frame the typical range for Cash & Equivalents.
- Annual changes were most pronounced in 2022 — Cash & Equivalents surged 149361.29% — and 2025, when it tumbled 87.23%.
- Canton Strategic Holdings' Cash & Equivalents stood at $6.5 million in 2022, then jumped by 67.96% to $10.9 million in 2023, then plunged by 67.45% to $3.6 million in 2024, then soared by 378.53% to $17.0 million in 2025, then soared by 143.84% to $41.5 million in 2026.
- Business Quant data shows CNTN's Cash & Equivalents at $41.5 million in Q1 2026, $17.0 million in Q4 2025, and $7.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,681.27 Bn | 66,680.98 Bn | - | 82.45 Mn |
| 2 | Nanobiotix | 1,942.19 Bn | 1,942.13 Bn | - | 61.40 Mn |
| 3 | Akari Therapeutics | 1,132.35 Bn | 1,132.35 Bn | - | 2.83 Mn |
| 4 | BeOne Medicines | 475.46 Bn | 470.67 Bn | 1.35 Bn | 4.79 Bn |
| 5 | Vertex Pharmaceuticals | 123.19 Bn | 115.94 Bn | 2.59 Bn | 5.49 Bn |
| 6 | Regeneron Pharmaceuticals | 69.44 Bn | 60.69 Bn | 3.31 Bn | 2.96 Bn |
| 7 | Belite Bio | 63.20 Bn | 63.20 Bn | - | - |
| 8 | Argenx Se | 57.08 Bn | 51.90 Bn | 1.41 Bn | 3.58 Bn |
| 9 | Revolution Medicines | 38.11 Bn | 38.11 Bn | - | 440.94 Mn |
| 10 | Canton Strategic Holdings | 428.91 Mn | 428.91 Mn | - | 41.53 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 41.53 Mn |
| Dec 31, 2025 | 17.03 Mn |
| Sep 30, 2025 | 7.61 Mn |
| Jun 30, 2025 | 2.24 Mn |
| Mar 31, 2025 | 1.08 Mn |
| Dec 31, 2024 | 3.56 Mn |
| Sep 30, 2024 | 4.77 Mn |
| Jun 30, 2024 | 7.90 Mn |
| Mar 31, 2024 | 8.43 Mn |
| Dec 31, 2023 | 10.94 Mn |
| Sep 30, 2023 | 2.69 Mn |
| Jun 30, 2023 | 3.90 Mn |
| Mar 31, 2023 | 3.57 Mn |
| Dec 31, 2022 | 6.51 Mn |
| Sep 30, 2022 | 7.60 Mn |
| Jun 30, 2022 | 9.48 Mn |
| Mar 31, 2022 | 11.12 Mn |
| Dec 31, 2021 | 4,356.00 |
| Sep 30, 2021 | 45,095.00 |
| Jun 30, 2021 | 29,271.00 |